Suppr超能文献

法舒地尔对健康志愿者中美华法林药代动力学和药效学的影响。

Effects of fesoterodine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.

机构信息

Pfizer Inc., New York, NY, USA.

出版信息

Br J Clin Pharmacol. 2011 Aug;72(2):257-62. doi: 10.1111/j.1365-2125.2011.03989.x.

Abstract

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT

Drug-drug interactions with warfarin are common with potentially harmful consequences. Preclinical in vitro studies suggest that fesoterodine or 5-hydroxymethyl tolterodine are not likely to affect warfarin metabolism, but a lack of interaction has not been demonstrated in a clinical study.

WHAT THIS STUDY ADDS

This study shows that the pharmacokinetics and pharmacodynamics of warfarin 25 mg in healthy adults are unaffected by fesoterodine 8 mg, and that co-administration of warfarin 25 mg and fesoterodine 8 mg is safe and well tolerated.

AIMS

To confirm the lack of an interaction of fesoterodine 8 mg with warfarin pharmacokinetics and pharmacodynamics in healthy adults.

METHODS

In this open-label, two-treatment, crossover study, subjects (n= 14) aged 20-41 years with normal prothrombin time (PT) and International Normalized Ratio (INR) were randomized to receive a single dose of warfarin 25 mg alone in one period and fesoterodine 8 mg once daily on days 1-9 with a single dose of warfarin 25 mg co-administered on day 3 in the other period. There was a 10-day washout between treatments. Pharmacokinetic endpoints were area under the plasma concentration-time curve from time 0 to infinity (AUC(0,∞)), maximum plasma concentration (C(max)), AUC from time 0 to the time of the last quantifiable concentration (AUC(0,last)), time to C(max) (t(max) ), and half-life (t(1/2)) for S- and R-warfarin. Pharmacodynamic endpoints were area under the INR-time curve (AUC(INR) ), maximum INR (INR(max)), area under the PT-time curve (AUC(PT)) and maximum PT (PT(max)).

RESULTS

Across all pharmacokinetic and pharmacodynamic comparisons, the point estimates of treatment ratio (warfarin co-administered with fesoterodine vs. warfarin alone) were 92-100%. The 90% confidence intervals for the ratios of the adjusted geometric means were contained within (80%, 125%). There were no clinically relevant changes in laboratory tests, vital signs or ECG recordings.

CONCLUSIONS

The pharmacokinetics and pharmacodynamics of warfarin 25 mg in healthy adults are unaffected by fesoterodine 8 mg. Concomitant administration of fesoterodine and warfarin was well tolerated.

摘要

已知关于该主题的信息

华法林与药物相互作用很常见,可能具有潜在的有害后果。临床前体外研究表明,非索罗定或 5-羟甲基托特罗定不太可能影响华法林的代谢,但在临床研究中尚未证明存在相互作用。

本研究的结果

本研究表明,健康成年人服用 25 毫克华法林时,非索罗定 8 毫克不会影响华法林的药代动力学和药效学,并且同时服用 25 毫克华法林和非索罗定是安全且耐受良好的。

目的

确认非索罗定 8 毫克与健康成年人华法林药代动力学和药效学无相互作用。

方法

在这项开放标签、两治疗、交叉研究中,年龄在 20-41 岁之间、凝血酶原时间(PT)和国际标准化比值(INR)正常的受试者(n=14)被随机分为两组,一组在一个周期内单独服用 25 毫克华法林,另一组在一个周期内每天服用 8 毫克非索罗定,连续服用 9 天,在第 3 天同时服用 25 毫克华法林。两种治疗方案之间有 10 天的洗脱期。药代动力学终点为从 0 到无穷大的血浆浓度-时间曲线下面积(AUC(0,∞))、最大血浆浓度(C(max))、从 0 到最后可定量浓度的时间的 AUC(AUC(0,last))、C(max)时间(t(max))和 S-和 R-华法林的半衰期(t(1/2))。药效学终点为 INR-时间曲线下面积(AUC(INR))、最大 INR(INR(max))、PT-时间曲线下面积(AUC(PT))和最大 PT(PT(max))。

结果

在所有药代动力学和药效学比较中,治疗比值(与非索罗定合用的华法林与单独使用的华法林)的点估计值为 92-100%。比值的 90%置信区间包含在(80%,125%)内。实验室检查、生命体征或心电图记录均无临床相关变化。

结论

健康成年人服用 25 毫克华法林时,非索罗定 8 毫克不会影响华法林的药代动力学和药效学。同时服用非索罗定和华法林耐受性良好。

相似文献

1
Effects of fesoterodine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.
Br J Clin Pharmacol. 2011 Aug;72(2):257-62. doi: 10.1111/j.1365-2125.2011.03989.x.
3
Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects.
Br J Clin Pharmacol. 2011 Aug;72(2):263-9. doi: 10.1111/j.1365-2125.2011.04007.x.
6
Lack of effect of lacosamide on the pharmacokinetic and pharmacodynamic profiles of warfarin.
Epilepsia. 2013 Jul;54(7):1161-6. doi: 10.1111/epi.12192. Epub 2013 Apr 24.
7
Lack of a meaningful effect of anacetrapib on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.
Br J Clin Pharmacol. 2012 Jul;74(1):116-24. doi: 10.1111/j.1365-2125.2012.04171.x.
8
Effect of linagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.
Int J Clin Pharmacol Ther. 2011 May;49(5):300-10. doi: 10.5414/cp201507.
9
The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers.
Br J Clin Pharmacol. 2009 May;67(5):527-34. doi: 10.1111/j.1365-2125.2009.03384.x. Epub 2009 Feb 4.

引用本文的文献

本文引用的文献

1
Fesoterodine for the treatment of urinary incontinence and overactive bladder.
Ther Clin Risk Manag. 2009;5:869-76. doi: 10.2147/tcrm.s6483. Epub 2009 Nov 18.
2
Guide to Receptors and Channels (GRAC), 4th Edition.
Br J Pharmacol. 2009 Nov;158 Suppl 1(Suppl 1):S1-254. doi: 10.1111/j.1476-5381.2009.00499.x.
3
Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence.
Curr Opin Urol. 2009 Jul;19(4):380-94. doi: 10.1097/MOU.0b013e32832ce8a4.
4
Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome.
Expert Opin Pharmacother. 2008 Jul;9(10):1787-96. doi: 10.1517/14656566.9.10.1787.
7
Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study.
Eur Urol. 2006 Dec;50(6):1306-14; discussion 1314-5. doi: 10.1016/j.eururo.2006.09.019. Epub 2006 Oct 2.
8
Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.
Chest. 2001 Jan;119(1 Suppl):8S-21S. doi: 10.1378/chest.119.1_suppl.8s.
9
Role of anticoagulant therapy in atrial fibrillation.
J Cardiovasc Electrophysiol. 1998 Aug;9(8 Suppl):S86-96.
10
Human P450 metabolism of warfarin.
Pharmacol Ther. 1997;73(1):67-74. doi: 10.1016/s0163-7258(96)00140-4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验